AT-12 PHASE 1/2 STUDY OF TH-302, INVESTIGATIONAL HYPOXIA-ACTIVATED PRODRUG, AND BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

BACKGROUND: Hypoxia is implicated in the pathogenesis of glioblastoma multiforme (GBM), and greater hypoxic burden is associated with poorer outcomes in GBM. Treatment with bevacizumab (BEV) may increase intratumoral hypoxia. An ongoing phase 1/2 study (NCT01403610) investigates safety and activity...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Brenner, Andrew, Floyd, John, Eng, Clarence, Kroll, Stew, Fichtel, Lisa, Gruslova, Aleksandra, Lodi, Alessia, Tiziani, Stefano
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2014
Fag:
Abstracts
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217789/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.12
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker